Endocrine Abstracts

Introduction: PNETs are rare with an annual incidence of 5 per million population. 75 % of pancreatic NET are functioning, PTHrP secretion regarded as a rarer entity and few case reports have been identified worldwide. Surgical resection is definitive management, however SSA treatment and Peptide Receptor Radionuclide Therapy (PRRT) have shown promising results in reducing PTHrP secretion.Case report: Here we describe a 61 years old lady who presented wi...

Introduction: Carcinoid heart disease can occur in up to 20 % of patients with carcinoid syndrome. It is a regarded as a rare complication and associated with high morbidity and mortality as a sequela of vasoactive peptides resulting in plaque formation on the valve leaflets classically tricuspid and pulmonary valves and causing right heart failure. Definitive treatment is surgical valve replacement, but percutaneous valve management is an attractive alternative for those deem...

Introduction: Established guidelines recommend carefully selected patients with Carcinoid Heart Disease (CHD) may undergo surgical valve replacement as definitive management. Right sided heart valve involvement is classical, occurring as result of plaque deposition on valve leaflets as a consequence of vasoactive peptides secreted by the NET because of carcinoid syndrome. Tricuspid and Pulmonary valve involvement leads to right heart failure (RHF) increasing mortality and morb...

Background: Cranial Diabetes Insipidus (CDI) or Arginine-Vasopressin Deficiency (AVP-D) is a potentially life-threatening condition requiring treatment with desmopressin. Omission or delay in desmopressin can result in serious patient harm.Aims: Evaluation of desmopressin prescription/administration practice and implementation of an action plan to improve patient safety.Methods: Re...